BioCentury
ARTICLE | Finance

Monthly money

Once-monthly human growth hormone draws Aisling to invest in Versartis

January 21, 2013 8:00 AM UTC

Versartis Inc. expects last week's $25 million series C round will get it to a Phase Ib/IIa data event for a long-acting recombinant human growth hormone to treat growth hormone deficiency. The product's once-monthly dosing would trump both the marketed daily version of hGH and the handful of once-weekly versions in the clinic.

The company's VRS-317 rhGH was developed using XTEN technology fromAmunix Inc.Versartis has rights to the compound from Amunix...